The Importance of Second Opinions for Sarcoma |
An ESUN Article
Because sarcoma is a rare cancer, most physicians may only encounter a few instances of it in their lifetime, if any at all. Patients need to be diagnosed and treated by physicians and interdisciplinary teams that have experience with sarcomas.
If you are diagnosed with sarcoma, we encourage you to obtain a second opinion about your initial diagnosis and your proposed treatment plan from a sarcoma center. Good physicians are not offended when patients seek a second opinion about a rare cancer; it is fairly standard procedure. Moreover, some insurance companies require a second opinion before they will reimburse costs for a proposed treatment plan.
Patients, family and caregivers dealing with cancer get advice from a lot of people. They get advice about their eating habits (where to buy food, how to cook it, what’s healthy, and what’s not), their lifestyles (not enough of this, too much of that, too dangerous, too sedentary), the way they manage changes to their bodies (especially their hair! wig, no wig?) and how to settle their affairs (not just legally, but with the great beyond).
They also get advice regarding whether or not they should get a second opinion. While getting a second opinion is generally considered a useful thing to do, there is a common misconception that it is a time-consuming and possibly expensive activity that often produces no change to treatment plans or long-term prognosis. However, several studies show that, for sarcoma patients, getting input from more than one medical professional can indeed make a difference, not only in medical decision-making, but also in the patient’s ultimate outcome. This article examines evidence which proves the value of obtaining a second opinion from a sarcoma specialist at critical junctures in the diagnosis and treatment of sarcoma.
Second Opinion of the Initial Diagnosis
Once a lesion has been determined to be a tumor that requires further evaluation, the patient’s journey begins. Getting a precise clinical assessment and finding out the exact type of a tumor is essential in getting patients onto the right treatment path quickly. The ideal time for a second consultation is before any incision has been made into the tumor.
In a 2005 article "Surgical Management of Soft Tissue Tumors: Avoiding the Pitfalls,"Drs. Fritz and Frederick Eilber of the UCLA School of Medicine state that, "In the presence of any clinical features that raise the suspicion of a sarcoma, appropriate cross-sectional imaging and tissue diagnosis are critical in guiding additional care." They go on to specify that "CT-guided core biopsy is the best method to obtain an accurate tissue diagnosis"[1]. Because the biopsy is guided by CT imaging, surgeons are able to collect samples with precision, improving the accuracy of the initial diagnosis [1]. The view that excisional biopsy is superior to needle biopsy is at best controversial and not reflective of practice at most major centers.
The authors of a study conducted by researchers at St Thomas Hospital in London, England link the use of excisional biopsies (in which an attempt is made to remove the entire lesion or tumor), instead of needle biopsies, to contamination of surrounding tissue, making it difficult to ensure that sufficient margins are achieved during initial surgery for soft tissue sarcoma [2].
Further support for a second opinion of an initial diagnosis is found in a study of over 600 patients having sarcoma-related surgery at BG University Hospital Bergmannsheil in Bochum, Germany [3]. The researchers first note the difficulty in obtaining a definitive diagnosis for soft tissue sarcoma because there are so many different types, stating "approximately 50 different histological subtypes of soft tissue sarcomas have been described"[3]. The results of their study reveal how important it is that the diagnosing pathologist has experience with the pathology of sarcoma. The findings of expert second opinions agreed with those of the primary diagnosis, by non-expert pathologists, as follows:
| Type of Initial Diagnosing Institution |
% Concordant with Expert Second Opinion |
|---|---|
Private Clinics
| 28.3% |
Hospitals
| 29.6% |
Academic Medical Centers
| 36.8% |
Department of Pathology at BG University Hospital
| 70.5% |
These results make a striking case for review of initial diagnosis before treatment is selected. Regarding treatment, one popular web-based medical information resource, WebMD, lists a rare cancers diagnosis as the number one reason to see a specialist for a second opinion on the diagnosis. "After all," the authors state "the diagnosis will determine which treatment is best" [4].
Another very interesting study advocates for mandatory second opinions of the original tissue samples before any treatment is given. This study, "Mandatory Second Opinion Surgical Pathology at a Large Referral Hospital" was conducted at John Hopkins Medical Institution in Baltimore, MD. In this study, a changed diagnosis was defined as one that "resulted in a significant change in therapy or prognosis" [5]. It found not only that, "Of 6,171 cases reviewed, second opinion surgical pathology resulted in 86 changed diagnosis (1.4%)", but also estimates that "The financial benefit averaged $2-4 saved for every $1 spent to obtain the second opinion!" [5]
The studies discussed above certainly make the case that initial diagnoses can be wrong and should be double-checked. The question then becomes: what difference does it make if a sarcoma diagnosis is a bit off, maybe just in the determination of subtype or grade? How different are sarcoma treatment protocols? Are these differences significant? We will now address these questions.
The Impact of the diagnosis on the Treatment Plan
Indeed, one significant risk of an incorrect or imprecise diagnosis is the impact on the treatment plan, including the choice to employ chemotherapy, whether to radiate, if and when to perform surgery and the surgical method to be used.
An area of particular concern is the risk of surgical error in the initial surgery done to remove the primary tumor. In the study "Surgical Resection of Primary Soft-Tissue Sarcoma," researchers from St Thomas’ Hospital in London examine records of patients who had previously undergone surgery to remove sarcoma tumors, but then had to have additional surgery because the initial surgery failed to remove all of the sarcoma cells from the area around the tumor [2]. Of the patients studied, over 56% were found to have residual tumor and 33% had tumors visible to the naked eye [2]. How does this happen?
What they found was that the first surgery had often used what is called a "shell out" procedure, done without having first obtained a complete pathological diagnosis [2]. They state "… the commonest reason was surgical excision without a prior biopsy for histological diagnosis, and … this had led to the use of a shell-out procedure" [2]. The shell-out procedure is a surgical method used for benign tumors that are well-defined masses. They’re easy to scoop out along the existing division between the tumor and the healthy tissue around it. Because some sarcomas look as if they have clear boundaries, surgeons can get the misleading impression that the tumor is benign and that it can safely be removed along its borders without excising additional tissue around it [2]. That study concludes, in part, that "surgical assessment of the adequacy of excision is very inaccurate and that most local recurrences are the consequence of inadequate primary surgery" [2].
Please see these related ESUN articles for more information:
The Margin Matters: Someone's Life Depends on It
Salvage of the Unplanned Sarcoma Excision
The National Comprehensive Cancer Network provides Clinical Practice Guidelines in Oncology, which are detailed yet concise planning documents that are extremely useful in understanding how decisions are made in the management of sarcoma therapy [6, 7]. The guidelines cover the various activities and principles associated with sarcoma treatment, including initial diagnostic evaluation, primary treatment, pre- and post- surgical therapy, radiation therapy, chemotherapy, progressive and recurrent disease, and follow-up [6]. Unique guidelines exist for soft tissue sarcomas of the extremities, retroperitoneal/abdominal, intra-abdominal and desmoid types [6]. For bone-related sarcomas, there are separate guidelines for chondrosarcoma, Ewing’s sarcoma, osteosarcoma, plus some variants [7]. Even a quick overview of these guidelines makes it clear that the assessments of the disease must be accurate in order for treatment based on these guidelines to be effective.
Financial Assistance for Second Opinions
Patients, caregivers and families grappling with the enormity of their diagnosis and the strain of day-to-day care may not believe they have the means or the energy to advocate on their own behalf and actively search for the best source(s) of a second opinion. However, help is available. Sarcoma support groups are great resources to get up-to-date information from people who are familiar with the process. They can help members locate local resources as well as connect each other with national programs that provide assistance with the costs of travel, lodging, and other expenses that insurance won’t cover.
A good example is the Sarcoma Alliance’s Hand in Hand program. This program "offers financial assistance for second opinion consultations by reimbursing expenses related to travel, phone bills, costs of the evaluation, and related expenses.”
Major sarcoma centers can supply information on the availability of free or discounted housing provided by organizations including The American Cancer Society's Hope Lodge, the Ronald McDonald Houses, and the local hotel industry.
Expenses (and patient stress!) can be further reduced when a working relationship is developed between a local oncology practice and a major sarcoma center. Sarcoma centers are often willing to provide the expert diagnosis and the treatment protocol, which can then be carried out closer to the patient’s home. For adults, outpatient treatment may also be an option.
For more information about financial assistance, view our Sarcoma Support Resources.
Summary
In summarizing the results of the "Mandatory Second Opinion" study, John Hopkins researchers point out that "Although a policy of mandatory second opinion surgical pathology for referred patients makes good clinical and risk management sense .... current trends in medical economics has placed this and other quality assurance practice at possible risk." [5]
From a caregiver perspective, this author sees that patients with a new sarcoma diagnosis need to be advised of the value of a second opinion on the diagnosis. There is always a great sense of urgency to begin treatment as soon as possible, so patients and their families may be wary of any delays. They need to be assured that expedited communication between the diagnosing facility and a major sarcoma center regarding diagnosis will reduce the amount of time between diagnosis and treatment and this is time well spent. No patient can afford to lose time pursuing the wrong treatment due to incorrect diagnosis. Remediating the effects of wrong treatments and procedures, after the mistake is recognized, cannot always be done.
Arizona
Mayo Clinic
Mayo Clinic specialists work as a multidisciplinary team to diagnose and treat all types of sarcoma. Physicians and researchers are dedicated to providing the most effective treatment possible. Mayo Clinic has earned an international reputation for its expertise in treating soft tissue sarcomas in adults and children, and hundreds of patients with bone tumors receive treatment at Mayo Clinic each year.
California
Cedars-Sinai Cancer Program
Cedars-Sinai, located in Los Angeles, is a patient-centered, comprehensive and specialized cancer program. On their website, they state, "At the Cedars-Sinai Cancer Program, dozens of nationally recognized programs and services are all under one interconnected, medical "roof"--an important benefit to cancer sufferers. Patients can be confident that every resource of this remarkable organization is brought to bear in delivering leading-edge healthcare services."
UCLA Sarcoma Program
The UCLA Sarcoma Program provides innovative multidisciplinary treatment for adults and children with sarcoma at any stage of the disease. UCLA is one of the three busiest sarcoma centers in the nation. On an annual basis they evaluate over 800 patients with sarcoma, 500 of which undergo surgery at UCLA. At our weekly sarcoma conference physicians specializing in sarcoma from surgical oncology, orthopedic oncology, medical oncology, radiation oncology, pediatric oncology, pathology and radiology formulate and coordinated optimal treatment strategies for individual patients.
Florida
H. Lee Moffitt Cancer Center and Research InstituteThe H. Lee Moffitt Cancer Center and Research Institute located at the University of South Florida in North Tampa, Florida brings together experts from a variety of cancer specialties to determine the best treatment plan for each patient, while linking together the Center’s extensive array of support services. As part of a group of National Cancer Institute Comprehensive Cancer Centers, Moffitt focuses on the development of early stage translational research aimed at the rapid translation of scientific discoveries to benefit patient care. The Sarcoma Program at the center takes an interdisciplinary approach to treating sarcomas.
Mayo Clinic
Mayo Clinic specialists work as a multidisciplinary team to diagnose and treat all types of sarcoma. Physicians and researchers are dedicated to providing the most effective treatment possible. Mayo Clinic has earned an international reputation for its expertise in treating soft tissue sarcomas in adults and children, and hundreds of patients with bone tumors receive treatment at Mayo Clinic each year.
Indiana
Simon Cancer Center, Indiana University
The Sarcoma Program of the IU Simon Cancer Center offers multidisciplinary care for both adults and children with benign or malignant bone or soft tissue lesions and patients with metastatic bone cancer. The multidisciplinary team is comprised of specialists in medical oncology, orthopedic surgery, as well as dietitians, physical and occupational therapists, psychologists and social workers.
Iowa
The Holden Comprehensive Cancer Center
The Holden Comprehensive Cancer Center, located at the University of Iowa Hospitals & Clinics, has a focus group called the "Sarcoma Tumor Board Multidisciplinary Team." This is a group of physicians who meet twice a month to discuss cases and care plans and to gain a better understanding of the roles they each play in the treatment of sarcoma.
Kansas
Sarcoma Institute at Menorah Medical Center
The Sarcoma Institute at Menorah Medical Center is a multi-disciplinary team of physicians, nurses, and allied health professionals dedicated to the care and treatment of patients with bone and soft tissues tumors. From infants to seniors, the professionals of the Sarcoma Institute treat patients with both primary malignant and benign tumors of the bone and soft tissues, as well as metastatic cancer of the bone. The Institute provides state-of-the-art treatments including surgical, medical and radiation, in a combined modality to offer patients the most effective care. Both research and education play a crucial role in the Institute by enhancing patient knowledge and continuing to enhance the field of sarcoma. The Institute is located in Overland Park, Kansas.
Maryland
The Johns Hopkins Sarcoma Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Located in Baltimore, Maryland, The Sarcoma Center at Johns Hopkins provides comprehensive care for pediatric and young adult patients with bone and soft tissue sarcomas. The Center uses a multidisciplinary team approach to care and treatment, which includes pediatric and adult medical oncology, surgery, pathology, diagnostic radiology, orthopaedics, radiotherapy and plastic surgery. Cases are reviewed by a multidisciplinary team at weekly conferences.
Massachusetts
Dana-Farber Cancer Institute
Located in Boston, Massachusetts, the Dana Farber Cancer Institute is a teaching affiliate of the Harvard Medical School. On their website, they state, "The Center for Sarcoma and Bone Oncology has dedicated specialty expertise in the pathologic and radiologic assessment of sarcoma, the application of novel soft-tissue and bone reconstructive techniques permitting limb salvage, and access to the most promising new therapies for these malignancies."
Massachusetts General Hospital
Center for Sarcoma & Connective Tissue Oncology
Michigan
University of Michigan Comprehensive Cancer Center
Located in Ann Arbor, Michigan, the UM Comprehensive Cancer Center is associated the UM's Medical School. On their website, they state, "The Center was established in 1986, and soon after was designated a "comprehensive" center by the National Cancer Institute. he U-M Cancer Center has more than 200 cancer clinicians and researchers. These specialists work together in multidisciplinary teams to rapidly bring new prevention, detection and treatment discoveries to more than 25 cancer care clinics."
Minnesota
Mayo Clinic
Mayo Clinic specialists work as a multidisciplinary team to diagnose and treat all types of sarcoma. Physicians and researchers are dedicated to providing the most effective treatment possible. Mayo Clinic has earned an international reputation for its expertise in treating soft tissue sarcomas in adults and children, and hundreds of patients with bone tumors receive treatment at Mayo Clinic each year.
New York
Columbia Weill Cornell Cancer Center at the Herbert Irving Comprehensive Cancer Center
Located in New York City, the Columbia Weill Cornell Cancer Center is part of the Herbert Irving Comprehensive Cancer Center in the New York-Presbyterian complex, which forms the university hospitals for Columbia University and Cornell University. On their website, they state, "Columbia Weill Cornell Cancer Centers provide comprehensive care for children and adults with primary and metastatic bone and soft tissue tumors."
Memorial Sloan-Kettering Cancer Center (MSK or MSKCC)
Located in New York City, Memorial Sloan-Kettering Cancer Center (MSKCC) has been dealing in cancer treatment and care for over 100-years. On their website, they state, "Memorial Sloan-Kettering doctors generate more than half of the world's research publications on soft-tissue sarcomas and have probably the largest experience with these tumors of any medical group."
Roswell Park Cancer Institute (RPCI)
The Roswell Park Cancer Institute (RPCI) locate in Buffalo, New York, is a National Cancer Institute designated comprehensive cancer center. RPCI patients benefit from a customized, comprehensive care program developed by a multidisciplinary team of cancer specialists. The program addresses the medical, nutritional, emotional, and spiritual needs of each patient from diagnosis through treatment and rehabilitation, discharge and follow-up care. Roswell Park Cancer Institute’s (RPCI) experts in soft-tissue sarcoma include specialists in surgery, medical oncology, radiation oncology, diagnostic radiology, pathology and rehabilitation support. Treatment approaches for this disease include conservative operations, combined with radiation therapy and/or chemotherapy, which offer patients a high rate of tumor control while avoiding amputation.
North Carolina
Duke University Medical Center
The Duke Sarcoma Program at Duke University Medical Center is a multi-disciplinary team of physicians, nurses, and allied health professionals dedicated to the care and treatment of patients with sarcoma. From infants to seniors, this team of professionals treat patients with both primary sarcomas of the bone and soft tissues,as well as metastatic sarcoma.. We provide state-of-the-art treatments including surgical oncology, adult and pediatric medical oncology and radiation oncology, in a multi-disciplinary clinical setting to offer patients the most effective care. Our specialists work closely together on basic scientific and clinical research in hopes of identifying improved detection and treatment of sarcoma. Duke University Medical Center is located in Durham, North Carolina.
Ohio
The Arthur James Cancer Hospital at The Ohio State University
The Arthur James Cancer Hospital at The Ohio State University is the largest sarcoma program in Ohio and one of the largest in the Midwest. The hospital has a complete sarcoma program with all specialties including orthopedic oncology, surgical oncology, adult and pediatric medical oncology, plastic surgery, pathology, radiation oncology, and radiology. Physicians in the program take care of more than 175 new sarcoma patients each year and have thousands of patients in long term follow-up.
Oregon
Oregon Health & Science University Sarcoma Program
Pennsylvania
Fox Chase Cancer Center (FCCC)
Located in Philadelphia, Pennsylvania, Fox Chase Cancer Center (FCCC) is an independent, nonprofit institution devoted to improving cancer treatment and prevention. In 1904, the Fox Chase Cancer Center Hospital, which was then called the American Oncologic Hospital, became the country's first cancer hospital. The Center was formed in 1974 to unite the Hospital with the Institute for Cancer Research, founded in 1927.
Texas
M. D. Anderson Cancer Center
Located in Houston, Texas, M. D. Anderson has built a "worldwide reputation for excellence in cancer patient care, research, education and prevention". On their website, they state, "Patients at M. D. Anderson's Sarcoma Center have a five-year survival rate well above the national average, and an outstanding 80% rate for classical osteosarcoma. Our center diagnoses, treats and manages sarcomas of the soft tissue and bone, using the latest technology available."
Utah
Huntsman Cancer Institute (University of Utah)
Located in Salt Lake City, Utah, The Huntsman Cancer institute operates a hospital-based patient care center in association with the Health Sciences Center at the University of Utah. On their website, they state, "The Huntsman Cancer Institute Sarcoma Service, in addition to engaging in comprehensive clinical care, has ongoing, state of the art, basic science studies investigating the causes of sarcomas."
Washington
Seattle Cancer Care Alliance – Sarcoma Service
The Seattle Cancer Care Alliance (SCCA) is a partnership between three leading cancer centers: the Fred Hutchinson Cancer Research Center, UW Medicine, and Children's Hospital and Regional Medical Center. The Alliance’s Sarcoma Service, which began in 1986, offers sarcoma patients the best of the Pacific Northwest's world-class cancer research and patient-care practices. It sees about 500 adults and 200 children a year who are newly diagnosed with sarcomas of various types. The majority of its patients come from outside the Western Washington region. It offers a multidisciplinary approach to sarcoma treatment, including access to new treatments and procedures through clinical trials, innovative programs such as the Sarcoma PET Imaging Program, Sarcobase one of the first sarcoma patient registries in North America and the first at a cancer center, as well as overlapping pediatric and adult programs, to provide continuity of care to young patients who can continue to see the same doctors as they grow to adulthood.
Washington, DC
Washington Cancer Institute and Lombardi Cancer Center
Located in Washington, DC, The Washington Cancer Institute and Lombardi Cancer Center is affiliated with Georgetown University. On their website, they state, "We have extensive experience treating both bone and soft tissue tumors of the extremities, pelvis and shoulder girdle. We have performed more than 3,000 tumor operations since 1979. We are leaders in limb-sparing surgery and have pioneered many surgical techniques in use at this and other cancer centers."
References
1. "Surgical Management of Soft Tissue Tumors: Avoiding the Pitfalls", By Fritz C. Eilber, MD, and Frederick R. Eilber, MD, American Society of Clinical Oncology Educational Book. ASCO 2005.
2. Surgical resection of Primary Soft-Tissue Sarcomas, by J. R. Goodlad et al, Journal of Bone and Joint Surgery, 1966.
3. "The Value of Expert Second Opinion in Diagnosis of Soft Tissue Sarcomas", by Lehnhardt M, Daigeler A, Hauser J, Puls A, Soimaru C, Kuhnen C, Steinau HU, Journal of Surgical Oncology 2008; 97, pp 40–43.
4. 5 Diagnoses That Call for a Second Opinion: Experts tell WebMD about situations in which another medical viewpoint may be priceless.
5. "Mandatory Second Opinion Surgical Pathology at a Large Referral Hospital", by Joseph D. Kronz, M.D, William H. Westra, M.D, and Jonathan I. Epstein, M.D., Cancer. 1999 Dec 1;86 (11), pp. 2426-35.
6. NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma V.2.2008, National Comprehensive Cancer Network
7. NCCN Clinical Practice Guidelines in Oncology: Bone Cancer V.1.2009, National Comprehensive Cancer Network
V5N6 ESUN Copyright © 2008 Liddy Shriver Sarcoma Initiative.



